21-22
March
Erlangen, Germany
Presentation
Prof. Dr. Gaipl
On 14 June 2024, our industry symposium entitled “Quality-assured Hyperthermia and Flash Radiotherapy” took place as part of the 30th Congress of the German Society for Radiation Oncology (DEGRO).
The lecture “Do the immunological Effects of Hyperthermia and FLASH Radiotherapy go together?” by Prof. Dr Udo Gaipl is now available for download as a PDF.
View the detailed presentation in its entirety (PDF)Upcoming
Events
All Events
27-28
March
Erlangen, Germany
55. Hyperthermie-Arbeitstreffen des Atzelsberger Kreises
02-06
May
Vienna, Austria
ESTRO 2025 – The European Society for Radiotherapy and Oncology
23-24
May
Frankfurt, Germany
SarkomMeeting Frankfurt 2025
19-21
June
Dresden, Germany
DEGRO 2025 - 31. Kongress der Deutschen Gesellschaft für Radioonkologie
11-13
September
Davos, Switzerland
29th Annual SASRO Meeting 2025
07-08
November
Krems, Austria
42. ÖGRO Jahrestagung 2025
The HEAT trial
Prof. Dr. Issels
Pancreatic cancer: Hyperthermia trial demonstrates significantly improved post-recurrence survival
The randomized clinical trial "Hyperthermia European Adjuvant Trial" (HEAT) investigated regional hyperthermia (RHT) with cisplatin added to gemcitabine compared to chemotherapy with gemcitabine alone in the adjuvant treatment after resection of pancreatic cancer. The results show a significantly improved post-recurrence survival and a trend towards improved overall survival using Pyrexar Medical's BSD-2000 3D radiative hyperthermia system. Pancreatic cancer is one of the most common causes of cancer-related death worldwide. The HEAT trial was prematurely stopped in May 2018, when the modified FOLFIRINOX regimen replaced gemcitabine as standard therapy. The trial included a total of 117 patients with a median follow-up of 56.6 months.
